VeriChip Corp. & RECEPTORS LLC to Develop Sensor Systems to Detect Biological Threats Such as Swine Flu & other Illnesses
06 5월 2009 - 9:30PM
Business Wire
VeriChip Corporation (�VeriChip�) (NASDAQ: CHIP) and its
development partner RECEPTORS LLC, a technology company whose
AFFINITY by DESIGN� chemistry platform can be applied to the
development of selective binding products, today announced plans to
develop surveillance and point-of-care sensor systems that will
efficiently detect and identify the presence of a particular
biological threat such as influenza virus, Methicillin-resistant
Staphylococcus aureus (MRSA) or other illnesses. The companies will
published a white paper outlining the development of �An Integrated
Sensor System for the Detection of Bio-Threats from Pandemics to
Emerging Diseases to Bio-Terrorism,� which will be available May 7,
2009, on VeriChip�s website at www.verichipcorp.com.
The products currently in the marketplace to detect and identify
such biological threats fail to provide a comprehensive solution
for threat detection and, importantly, are not stable or scalable.
Additionally, current testing methods are typically too specific to
effectively screen for the broad range of potential agents. Current
methods also may require specialized sample handling in a
laboratory setting and take in excess of 24 hours to produce
results. The companies� products are expected to produce results
on-site within 20 minutes against a broad range of potential
biological threats in a method that is environmentally stable and
economically scalable.
Robert E. Carlson, Ph.D., President and Chief Science Officer at
RECEPTORS LLC, said, �Through our development partnership with
VeriChip, we are focused on building an integrated suite of
products that will identify a biological threat, from pandemic
influenza and multiple-resistant pathogens like MRSA, to food borne
illnesses such as salmonella and E. coli. The combination of our
CARA platform and VeriChip's signal transduction and communication
capabilities provide both the technology and the expertise required
to build the integrated bio-threat sensor system.�
Scott R. Silverman, Chairman of VeriChip, said, "As we continue
to build on our partnership with RECEPTORS, which started with the
development of a glucose-sensing RFID implantable microchip, we are
moving beyond patient identification to sensors that can detect and
identify illnesses and viruses such as influenza. This is an
exciting next step for the future of our healthcare division.�
Last week, VeriChip announced it has expanded its existing
development partnership with RECEPTORS, beyond the glucose-sensing
RFID implantable microchip to include other biological and
environmental applications. RECEPTORS recently received Patent No.
7,504,364 titled �Methods of Making Arrays and Artificial
Receptors� and Patent No. 7,469,076 �Sensors Employing
Combinatorial Artificial Receptors,� which are being applied to the
development of diagnostic and sensor platforms for pathogens and
other biological threats.
About RECEPTORS LLC
RECEPTORS LLC is a private company based in Chaska, Minnesota.
RECEPTORS' mission is to advance the diagnosis and treatment of
disease and to enhance the health, safety, and quality of the
global environment through the development and application of
artificial receptor products for both research and industry.
RECEPTORS' AFFINITY by DESIGN� technology is the foundation of its
SMART MATERIALS product platform. Each product incorporates
RECEPTORS' core competence of surface functionalization for
selective binding. This high-throughput approach to the development
of stable, selective and scalable binding environments can be
tailored to any product and application. For further information
please visit http://www.receptorsllc.com or email
info@receptorsllc.com.
About VeriChip
VeriChip Corporation, headquartered in Delray Beach, Florida,
has developed the VeriMed� Health Link System for rapidly and
accurately identifying people who arrive in an emergency room and
are unable to communicate. This system uses the first
human-implantable passive RFID microchip, cleared for medical use
in October 2004 by the United States Food and Drug Administration.
To complement its healthcare division, VeriChip Corporation
established VeriGreen Energy Corporation in March 2009 to focus and
invest in the clean and alternative energy sector.
For more information on VeriChip, please call 1-800-970-2447, or
e-mail info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.
Statements about VeriChip�s future expectations, including its
ability to develop and market a glucose-sensing microchip in
conjunction with its development partner RECEPTORS LLC, its ability
to expand its development partnership with RECEPTORS LLC to include
other biological and environmental applications, and the ability of
the biological and environmental applications that are to be
jointly developed and marketed by it and RECEPTORS LLC to detect,
among other things, influenza, swine flu MRSA, salmonella, E. coli,
and other proteins, and all other statements in this press release
other than historical facts are �forward-looking statements� within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934, and as that term is
defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and VeriChip�s actual results could
differ materially from expected results. Additional information
about these and other factors that could affect the Company�s
business is set forth in the Company�s various filings with the
Securities and Exchange Commission, including those set forth in
the Company�s 10-K filed on February 12, 2009, under the caption
�Risk Factors.� The Company undertakes no obligation to update or
release any revisions to these forward-looking statements to
reflect events or circumstances after the date of this statement or
to reflect the occurrence of unanticipated events, except as
required by law.
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
